XJPX
4543
Market cap21bUSD
Oct 09, Last price
2,284.00JPY
1D
-1.06%
1Q
4.34%
Jan 2017
5.86%
Name
Terumo Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
Related entities
Subsidiaries (3)
Terumo BCT Europe
TERUMO EUROPE
VASCUTEK LIMITED
Key people
Antoinette Gawin
Senior Managing Executive Officer, President of Blood System Company, President & Chief Executive Officer of Subsidiary · since 2024
Toshihiko Osada
Senior Managing Executive Officer, Director · since 2024
Fumihisa Hirose
Managing Executive Officer, President of Cardiac and Vascular Company, President of TIS Division of Cardiac and Vascular Company · since 2024
Norimasa Kunimoto
Managing Executive Officer, Director · since 2023
Itaru Sakaguchi
Managing Executive Officer, President of Medical Care Solutions Company · since 2024
Hiroshi Yagi
Managing Executive Officer, Chief Operations Officer (COO) of TIS Business in Cardiac and Vascular Company, President of Subsidiary · since 2025
Jin Nishizaki
Executive Officer, Chief Director of Domestic Sales · since 2022
Tomoko Adachi
Chief Human Resources Officer, Executive Officer · since 2023
Toshiyuki Akaike
Executive Officer, President of Hospital Care Solution Business in Medical Care Solutions Company · since 2023
Probir Das
Executive Officer, Chairman of Subsidiary · since 2022
Robert Deryke
Executive Officer, President of Cardiovascular Business in Cardiovascular Company, President and CEO of Subsidiary · since 2022
Ghada Farah
Group Executive Officer, President of Terumo Interventions Systems in Cardiac and Vascular Company · since 2025
Noritsugu Fujita
Executive Officer, President of Pharmaceutical Solutions Business in Medical Care Solutions Company · since 2024
Jin Hagimoto
Chief Financial Officer, Chief Information Officer, Executive Officer, Manager of CFO Office · since 2025
Kenichi Hata
Group Executive Officer, Manager of Business Planning Office · since 2024
Katsuyuki Honda
Executive Officer, President and CEO of Subsidiary · since 2023
Takuya Hosogai
Executive Officer, President and CEO of Subsidiary · since 2023
Yasuhiro Ikoma
Executive Officer, Chief Commercial Officer (CCO) of Terumo Interventional Systems in Cardiac and Vascular Company · since 2025
Satoshi Kawajiri
Group Executive Officer, President of Hospital Care Solutions in Medical Care Solutions Company · since 2025
Takeshi Kuroo
Executive Officer, Senior Vice President of Surgery in Cardiovascular Company, Manager of Heart Sheet Business Office in Cardiovascular Company · since 2022
Headquarters & legal address
幡ヶ谷二丁目44番1号
東京都 渋谷区 151-0072
JP
東京都 渋谷区 151-0072
JP
Address
2-44-1, Hatagaya
Shibuya-ku Tokyo 151-0072
JP
Shibuya-ku Tokyo 151-0072
JP
Other language
Terumo Corporation
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||